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Primary care services form the backbone of health care 
in most high-income countries. Yet, there are growing 
concerns about the eﬀ ects that numerous changes in 
the content and delivery of primary care have had on the 
workload of primary care practitioners. In a retrospective 
analysis in The Lancet, F D Richard Hobbs and colleagues1 
investigated the direct clinical workload of general 
practitioners (GPs) and practice nurses in primary care in 
the UK, and present data from consultations of patients 
registered at 398 English general practices between 
April, 2007, and March, 2014. 
Hobbs and colleagues1 used data from electronic 
health records in the Clinical Practice Research 
Datalink, and linked these data to national datasets 
that included more than 100 million consultations 
and 20 626 297 person-years of observation. The 
study ﬁ ndings show that the overall workload of GPs 
in England rose by 16% in the 7 years up to 2014, 
with more frequent and longer GP consultations. 
Rates of GP consultations rose by 12·36% per 10 000 
person-years, compared with 0·9% for practice 
nurses. Moderate rises in rates of GP face-to-face 
consultations (5·2%) were overshadowed by an 
almost 100% increase in the rate of GP telephone 
consultations. Additionally, the mean duration of 
GP face-to-face consultations rose by about half 
a minute, from 8·65 min (95% CI 8·64–8·65) in 
2007–08 to 9·22 min (9·22–9·23) in 2013–14. This 
rising tide of workload is probably an underestimate, 
since an additional 40% of GP time is spent on tasks 
not measured in this study, such as arrangement 
of referrals or admissions, renewal of prescriptions, 
administrative and clinical meetings, and teaching.2 
Moreover, although the dataset does not provide data 
about the number of GPs (which could account for the 
increase in consultations), the investigators point out 
that other data show there has been a 1% decline in 
full-time equivalent GPs over this time period.
These startling results reﬂ ect what we and many 
of our GP colleagues have experienced—a seemingly 
endless demand for consultations, coupled with 
more complex patient care, escalating administrative 
tasks, pressures to meet quality performance targets, 
and rising documentation requirements. A worrying 
amount of this work happens not just within 
consultations, but also afterwards, which can account 
for an estimated additional 8 h of work per week 
or more for an average GP.2 This struggle to provide 
the quality of care GPs would like to oﬀ er in the face 
of competing demands on time, is contributing to 
alarming rates of burnout. 54% of UK GPs older than 
50 years report a considerable or high likelihood of 
quitting direct patient care within 5 years, with 82% 
intending to leave or reduce their clinical work within 
the next 5 years.3,4 When GPs who have left the UK’s 
National Health Service (NHS) are asked why, they cite 
the negative impacts of administrative tasks and overall 
workload, and limited ability to provide patient-centred 
care.5 The lowest level of job satisfaction among GPs 
since 2001 is deeply concerning, and presumably 
reﬂ ects, among other things, the various changes 
to organisation of general practice in England under 
successive governments.2
Are GPs unique in the NHS in terms of their rising 
workload? Hobbs and colleagues focus on general 
practice, but rising workload has been documented 
in other areas of the NHS. For example, emergency 
admissions of children to hospital have risen by 28% in 
the past decade, with similar experiences in other parts 
of the health service.6,7 To some extent, the rise in GP 
workload parallels similar increases in overall health-care 
workload in the UK.
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Is rising GP workload an English NHS problem, 
or is it common to primary care in other countries? 
Surprisingly little information exists about consultation 
numbers and duration internationally, but other 
data suggest that English GPs are not alone. A 2008 
survey of family doctors in 12 European countries 
found burnout was a common issue, with 43% of 
family doctors experiencing burnout from emotional 
exhaustion.8 In the USA, almost half of primary care 
physicians have symptoms of burnout.9 The reasons for 
this unhappiness internationally mirror those of English 
GPs—increasing administrative burdens, greater 
expectations placed on primary care, time pressures, 
longer working days, and fewer rewards. Even in 
countries with greater investment in health care, such 
as the USA, as Sinsky and colleagues have remarked, 
“joy is in short demand”.10
Roland and Everington have warned that “If general 
practice fails, the whole NHS fails”.11 With the NHS’s 
budget under increasing ﬁ nancial pressure, what 
are practical solutions for achievement of a fully 
functioning and modern general practice? Increasing 
the supply of GP workforce is one solution, with 5000 
more GPs cited as being needed in the UK by 2020.12 
However, with “GP training, recruitment, and retention 
in the UK fast approaching crisis point”,5 recruitment 
of more GPs is unlikely to ﬁ x the problem in time. So, 
what are other solutions? Roland and Everington 
gave sensible suggestions about what is needed to 
revive general practice, including substantial ﬁ nancial 
investment in general practice and in the NHS overall, 
novel ways of improving communication between 
GPs and specialists, and improving recruitment and 
retention of GPs.11 We believe that a major shift is 
also needed in general practice, away from a doctor-
centric model to one that is truly a shared care model, 
in which more and varied types of clinical support 
staﬀ  (eg, nurses, pharmacists, physician assistants) 
work in collaboration with GPs. However, Hobbs and 
colleagues’ data show that English general practice 
is currently top heavy, with about three times more 
GP than nurse consultations.1 Expansion of the roles 
of diﬀ erent types of clinical support staﬀ , rather than 
simply employing more GPs, is an underused approach 
in the UK, leaving GPs to bear the burden.
Finally, what can be done to reduce demand for 






however much capacity is provided (supply), whether 
by telephone, in person, and in some settings over the 
internet, this capacity is rapidly ﬁ lled. Perhaps health-
care services might never be able to fully match demand. 
For example, a random survey of 49 706 individuals, 
representative of the Danish adult population, found 
that some symptoms such as tiredness were reported 
in 49·4% of individuals.13 GPs usually only see the tip 
of this so-called symptom iceberg, and might never 
be able to see (or should see) everyone with every 
symptom.13 If general practice in England is to survive, 
new approaches are needed to address the expectations 
of patients and to provide advice and health care that 
does not always have to involve GP consultations, and 
with no additional health-care costs.
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On May 9, 2016, the Indian Patent Oﬃ  ce granted the US 
pharmaceutical company Gilead a patent for sofosbuvir, 
a direct-acting antiviral for the treatment of hepatitis C 
virus (HCV).1 The decision to grant the patent reversed 
an earlier decision by the Indian Patent Oﬃ  ce to reject 
the application after civil society organisations and 
generic manufacturers had ﬁ led a formal opposition to 
the patent application.2 
The new sofosbuvir patent decision is again 
raising concerns among public health advocates. 
HCV infection can lead to lethal liver disease if left 
untreated. WHO estimates that 130–150 million people 
worldwide have chronic HCV infection, although recent 
estimates suggest this ﬁ gure could be lower, at around 
80 million.3,4 WHO has laid out a global strategy for 
the treatment and elimination of HCV and has added 
sofosbuvir and other HCV medicines to the WHO Model 
List of Essential Medicines.5,6 The implementation 
of such an ambitious strategy will depend on the 
availability of aﬀ ordable medicines.7 
Aﬀ ordability is central to the HCV issue. The price 
of a 12-week sofosbuvir treatment course of up to 
US$84 000 in the USA and €48 000 ($54 400) in the 
Netherlands,8 for example, is prohibitive for most health 
systems. In high-income and middle-income countries 
where generic HCV medicines are not accessible, the 
high price of HCV medication has led to the rationing 
of the treatment.8 The production cost of sofosbuvir 
is estimated to be $68–136 for a 12-week treatment 
course9 and is for sale in India for $500.10
India’s generics industry ﬂ ourished during the 
country’s decades-long ban on medicines product 
patents, and was able to produce generic copies of 
new medicines and oﬀ er them at much lower price. 
Indian generic antiretroviral medicines, for example, 
have been essential in the scale-up of HIV treatment.7 
This situation ended in 2005 when India amended its 
Patents Act to introduce medicines product patents to 
become compliant with the intellectual property rules 
of the World Trade Organization.11 As a result, since 
2005 pharmaceutical companies apply for medicines 
patents in India, which means that all new medicines 
can be subject to 20-year patents there. When a patent 
is granted, other manufacturers cannot produce a 
generic version of the medicine until the expiry of 
the patent. 
The grant of the sofosbuvir patent to Gilead does 
not mean that generic production and supply are 
impossible because of agreements between certain 
producers and Gilead that allow for generic production. 
In 2014, 11 Indian generic companies signed a 
voluntary licence agreement with Gilead for the 
production of the HCV medicines sofosbuvir, ledipasvir/
sofosbuvir combination tablet, and the investigational 
combination tablet sofosbuvir/velpatasvir.12 The 
Indian companies can supply in India and export 
to 100 low-income and middle-income countries, 
potentially providing access to the products for about 
100 million people living with HCV. The agreement also 
prohibits the generic companies from supplying these 
Indian hepatitis C drug patent decision shakes public 
health community
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